PURPOSE: Transplantation-related mortality (TRM) is a major barrier to the success of allogeneic hematopoietic cell transplantation (HCT). PATIENTS AND METHODS: We assessed changes in the incidence of TRM and overall survival from 1985 through 2004 in 5,972 patients younger than age 50 years who received myeloablative conditioning and HCT for acute myeloid leukemia (AML) in first complete remission (CR1) or second complete remission (CR2). RESULTS: Among HLA-matched sibling donor transplantation recipients, the relative risks (RRs) for TRM were 0.5 and 0.3 for 2000 to 2004 compared with those for 1985 to 1989 in patients in CR1 and CR2, respectively (P < .001). The RRs for all causes of mortality in the latter period were 0.73 (P = .001) and 0.60 (P = .005) for the CR1 and CR2 groups, respectively. Among unrelated donor transplantation recipients, the RRs for TRM were 0.73 (P = .095) and 0.58 (P < .001) for 2000 to 2004 compared with those in 1990 to 1994 in the CR1 and CR2 groups, respectively. Reductions in mortality were observed in the CR2 group (RR, 0.74; P = .03) but not in the CR1 group. CONCLUSION: Our results suggest that innovations in transplantation care since the 1980s and 1990s have reduced the risk of TRM in patients undergoing allogeneic HCT for AML and that this reduction has been accompanied by improvements in overall survival.
PURPOSE: Transplantation-related mortality (TRM) is a major barrier to the success of allogeneic hematopoietic cell transplantation (HCT). PATIENTS AND METHODS: We assessed changes in the incidence of TRM and overall survival from 1985 through 2004 in 5,972 patients younger than age 50 years who received myeloablative conditioning and HCT for acute myeloid leukemia (AML) in first complete remission (CR1) or second complete remission (CR2). RESULTS: Among HLA-matched sibling donor transplantation recipients, the relative risks (RRs) for TRM were 0.5 and 0.3 for 2000 to 2004 compared with those for 1985 to 1989 in patients in CR1 and CR2, respectively (P < .001). The RRs for all causes of mortality in the latter period were 0.73 (P = .001) and 0.60 (P = .005) for the CR1 and CR2 groups, respectively. Among unrelated donor transplantation recipients, the RRs for TRM were 0.73 (P = .095) and 0.58 (P < .001) for 2000 to 2004 compared with those in 1990 to 1994 in the CR1 and CR2 groups, respectively. Reductions in mortality were observed in the CR2 group (RR, 0.74; P = .03) but not in the CR1 group. CONCLUSION: Our results suggest that innovations in transplantation care since the 1980s and 1990s have reduced the risk of TRM in patients undergoing allogeneic HCT for AML and that this reduction has been accompanied by improvements in overall survival.
Authors: Stephen Couban; David R Simpson; Michael J Barnett; Christopher Bredeson; Lothar Hubesch; Kang Howson-Jan; Tsiporah B Shore; Irwin R Walker; Peter Browett; Hans A Messner; Tony Panzarella; Jeffrey H Lipton Journal: Blood Date: 2002-09-01 Impact factor: 22.113
Authors: H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas Journal: Transplantation Date: 1974-10 Impact factor: 4.939
Authors: M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum Journal: Blood Date: 2000-12-15 Impact factor: 22.113
Authors: Nancy Bunin; Michael Carston; Donna Wall; Roberta Adams; James Casper; Naynesh Kamani; Roberta King Journal: Blood Date: 2002-05-01 Impact factor: 22.113
Authors: G Hilbert; D Gruson; F Vargas; R Valentino; G Gbikpi-Benissan; M Dupon; J Reiffers; J P Cardinaud Journal: N Engl J Med Date: 2001-02-15 Impact factor: 91.245
Authors: W I Bensinger; P J Martin; B Storer; R Clift; S J Forman; R Negrin; A Kashyap; M E Flowers; K Lilleby; T R Chauncey; R Storb; F R Appelbaum Journal: N Engl J Med Date: 2001-01-18 Impact factor: 91.245
Authors: Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf Journal: Blood Date: 2004-06-10 Impact factor: 22.113
Authors: R S Weiner; M M Bortin; R P Gale; E Gluckman; H E Kay; H J Kolb; A J Hartz; A A Rimm Journal: Ann Intern Med Date: 1986-02 Impact factor: 25.391
Authors: Marcia Grant; Liz Cooke; Anna Cathy Williams; Smita Bhatia; Leslie Popplewell; Gwen Uman; Stephen Forman Journal: Support Care Cancer Date: 2012-02-09 Impact factor: 3.603
Authors: Christopher Bredeson; Jennifer LeRademacher; Kazunobu Kato; John F Dipersio; Edward Agura; Steven M Devine; Frederick R Appelbaum; Marcie R Tomblyn; Ginna G Laport; Xiaochun Zhu; Philip L McCarthy; Vincent T Ho; Kenneth R Cooke; Elizabeth Armstrong; Angela Smith; J Douglas Rizzo; Jeanne M Burkart; Marcelo C Pasquini Journal: Blood Date: 2013-09-30 Impact factor: 22.113
Authors: K Jordan; I J Christensen; M H Jørgensen; C Heilmann; H Sengeløv; K G Müller Journal: Bone Marrow Transplant Date: 2015-03-23 Impact factor: 5.483
Authors: Timothy S Sannes; Susan K Mikulich-Gilbertson; Crystal L Natvig; Benjamin W Brewer; Teresa L Simoneau; Mark L Laudenslager Journal: Cancer Nurs Date: 2018 Jan/Feb Impact factor: 2.592
Authors: A Kawajiri; S Fuji; Y Tanaka; C Kono; T Hirakawa; T Tanaka; R Ito; Y Inoue; K Okinaka; S Kurosawa; Y Inamoto; S-W Kim; T Yamashita; T Fukuda Journal: Bone Marrow Transplant Date: 2017-03-20 Impact factor: 5.483
Authors: A G Dinmohamed; O Visser; Y van Norden; N M A Blijlevens; J J Cornelissen; G A Huls; P C Huijgens; P Sonneveld; A A van de Loosdrecht; G J Ossenkoppele; B Löwenberg; M Jongen-Lavrencic Journal: Leukemia Date: 2015-07-17 Impact factor: 11.528
Authors: Lisa P Spees; Paul L Martin; Joanne Kurtzberg; Andre Stokhuyzen; Lauren McGill; Vinod K Prasad; Timothy A Driscoll; Suhag H Parikh; Kristin M Page; Richard Vinesett; Christopher Severyn; Anthony D Sung; Alan D Proia; Kirsten Jenkins; Mehreen Arshad; William J Steinbach; Patrick C Seed; Matthew S Kelly Journal: Biol Blood Marrow Transplant Date: 2018-11-24 Impact factor: 5.742
Authors: N Jaekel; G Behre; A Behning; C Wickenhauser; T Lange; D Niederwieser; H K Al-Ali Journal: Bone Marrow Transplant Date: 2013-12-02 Impact factor: 5.483